Cargando…

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers

c-Met is a well-characterized oncogene that is associated with poor prognosis in many solid tumor types. While responses to c-Met inhibitors have been observed in clinical trials, activity appears to be limited to those with MET gene amplifications or mutations. We developed a c-Met targeted antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Ryo, Blot, Vincent, Wong, Eley, Stewart, Christine, Lieuw, Vincent, Richardson, Robyn, Banah, Ammar, Villicana, Jose, Timmer, Anjuli, Coronella, Julia, Newman, Roland, Gymnopoulos, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515515/
https://www.ncbi.nlm.nih.gov/pubmed/32192391
http://dx.doi.org/10.1080/15384047.2020.1737490
_version_ 1783586826014949376
author Fujita, Ryo
Blot, Vincent
Wong, Eley
Stewart, Christine
Lieuw, Vincent
Richardson, Robyn
Banah, Ammar
Villicana, Jose
Timmer, Anjuli
Coronella, Julia
Newman, Roland
Gymnopoulos, Marco
author_facet Fujita, Ryo
Blot, Vincent
Wong, Eley
Stewart, Christine
Lieuw, Vincent
Richardson, Robyn
Banah, Ammar
Villicana, Jose
Timmer, Anjuli
Coronella, Julia
Newman, Roland
Gymnopoulos, Marco
author_sort Fujita, Ryo
collection PubMed
description c-Met is a well-characterized oncogene that is associated with poor prognosis in many solid tumor types. While responses to c-Met inhibitors have been observed in clinical trials, activity appears to be limited to those with MET gene amplifications or mutations. We developed a c-Met targeted antibody-drug conjugate (ADC) with preclinical activity in the absence of MET gene amplification or mutation, and activity even in the context of moderate protein expression. The ADC utilized a high-affinity c-Met antibody (P3D12), that induced c-Met degradation with minimal activation of c-Met signaling, or mitogenic effect. P3D12 was conjugated to the tubulin inhibitor toxin MMAF via a cleavable linker (vc-MMAF). P3D12-vc-MMAF demonstrated potent in vitro activity in c-Met protein-expressing cell lines regardless of MET gene amplification or mutation status, and retained activity in cell lines with medium-low c-Met protein expression. In contrast, the c-Met tyrosine kinase inhibitor (TKI) PHA-665752 slowed tumor cell growth in vitro only in the context of MET gene amplification or very high protein expression. This differential activity was even more marked in vivo. P3D12-vc-MMAF demonstrated robust inhibition of tumor growth in the MET gene amplified MKN-45 xenograft model, and similar results in H1975, which expresses moderate levels of wild type c-Met without genomic amplification. By comparison, the c-Met TKI, PHA-665752, demonstrated modest tumor growth inhibition in MKN-45, and no inhibition at all in H1975. Taken together, these data suggest that P3D12-vc-MMAF may have a superior clinical profile in treating c-Met positive malignancies in contrast to c-Met pathway inhibitors.
format Online
Article
Text
id pubmed-7515515
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-75155152020-10-01 A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers Fujita, Ryo Blot, Vincent Wong, Eley Stewart, Christine Lieuw, Vincent Richardson, Robyn Banah, Ammar Villicana, Jose Timmer, Anjuli Coronella, Julia Newman, Roland Gymnopoulos, Marco Cancer Biol Ther Research Paper c-Met is a well-characterized oncogene that is associated with poor prognosis in many solid tumor types. While responses to c-Met inhibitors have been observed in clinical trials, activity appears to be limited to those with MET gene amplifications or mutations. We developed a c-Met targeted antibody-drug conjugate (ADC) with preclinical activity in the absence of MET gene amplification or mutation, and activity even in the context of moderate protein expression. The ADC utilized a high-affinity c-Met antibody (P3D12), that induced c-Met degradation with minimal activation of c-Met signaling, or mitogenic effect. P3D12 was conjugated to the tubulin inhibitor toxin MMAF via a cleavable linker (vc-MMAF). P3D12-vc-MMAF demonstrated potent in vitro activity in c-Met protein-expressing cell lines regardless of MET gene amplification or mutation status, and retained activity in cell lines with medium-low c-Met protein expression. In contrast, the c-Met tyrosine kinase inhibitor (TKI) PHA-665752 slowed tumor cell growth in vitro only in the context of MET gene amplification or very high protein expression. This differential activity was even more marked in vivo. P3D12-vc-MMAF demonstrated robust inhibition of tumor growth in the MET gene amplified MKN-45 xenograft model, and similar results in H1975, which expresses moderate levels of wild type c-Met without genomic amplification. By comparison, the c-Met TKI, PHA-665752, demonstrated modest tumor growth inhibition in MKN-45, and no inhibition at all in H1975. Taken together, these data suggest that P3D12-vc-MMAF may have a superior clinical profile in treating c-Met positive malignancies in contrast to c-Met pathway inhibitors. Taylor & Francis 2020-03-19 /pmc/articles/PMC7515515/ /pubmed/32192391 http://dx.doi.org/10.1080/15384047.2020.1737490 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Research Paper
Fujita, Ryo
Blot, Vincent
Wong, Eley
Stewart, Christine
Lieuw, Vincent
Richardson, Robyn
Banah, Ammar
Villicana, Jose
Timmer, Anjuli
Coronella, Julia
Newman, Roland
Gymnopoulos, Marco
A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
title A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
title_full A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
title_fullStr A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
title_full_unstemmed A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
title_short A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
title_sort novel non-agonist c-met antibody drug conjugate with superior potency over a c-met tyrosine kinase inhibitor in c-met amplified and non-amplified cancers
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515515/
https://www.ncbi.nlm.nih.gov/pubmed/32192391
http://dx.doi.org/10.1080/15384047.2020.1737490
work_keys_str_mv AT fujitaryo anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT blotvincent anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT wongeley anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT stewartchristine anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT lieuwvincent anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT richardsonrobyn anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT banahammar anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT villicanajose anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT timmeranjuli anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT coronellajulia anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT newmanroland anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT gymnopoulosmarco anovelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT fujitaryo novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT blotvincent novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT wongeley novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT stewartchristine novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT lieuwvincent novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT richardsonrobyn novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT banahammar novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT villicanajose novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT timmeranjuli novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT coronellajulia novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT newmanroland novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers
AT gymnopoulosmarco novelnonagonistcmetantibodydrugconjugatewithsuperiorpotencyoveracmettyrosinekinaseinhibitorincmetamplifiedandnonamplifiedcancers